OTCMKTS:IDXG Interpace Biosciences 11/4/2024 Earnings Report $1.45 0.00 (0.00%) As of 08/26/2026 ProfileEarnings History Interpace Biosciences EPS ResultsActual EPS$0.31Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInterpace Biosciences Revenue ResultsActual Revenue$12.30 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInterpace Biosciences Announcement DetailsQuarterDate11/4/2024TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Interpace Biosciences Earnings HeadlinesPDI Gold Issues New Long-Dated Performance Rights Under Incentive SchemeSeptember 11 at 3:30 AM | tipranks.comPDO: Better Than PDI, Still Not Cheap EnoughSeptember 10 at 9:10 AM | seekingalpha.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 11 at 1:00 AM | Chaikin Analytics (Ad)PDI Gold Sets AGM Date and Deadline for Director NominationsSeptember 8 at 12:51 AM | tipranks.comEnabling Smarter Operations Across Latin America’s Fuel and Convenience Industry with PDI TechnologiesSeptember 4, 2026 | financialpost.comFPDI: Too Cheap To Sell, Too Risky To BuySeptember 4, 2026 | seekingalpha.comSee More Interpace Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Interpace Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Interpace Biosciences and other key companies, straight to your email. Email Address About Interpace BiosciencesInterpace Biosciences (OTCMKTS:IDXG) provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.View Interpace Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AeroVironment's Record Backlog and Earnings Beat Fuel Recovery CaseGameStop’s Comeback Case Is Getting Interesting, But eBay Still Looks StrongerChewy’s Sell-Off Puts Its Recurring Revenue Story Back on Trial for InvestorsWhy Braze’s Guidance Miss May Be a Gift for InvestorsCasey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality RetailerCathie Wood Trimmed Palantir, But the Bigger Story Is Still ValuationVictoria’s Secret’s Comeback Is Real—The Stock’s Problem Is Different Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
